British drugmaker GlaxoSmithKline Plc said on Wednesday it would cut about 650 positions in the United States related to a global restructuring program it announced in July.
The job cuts would include about 100 each in its back office in Philadelphia and at Research Triangle Park, North Carolina, and 450 sales representatives, GlaxoSmithKline spokeswoman Mary Anne Rhyne said in a statement.
The savings from these cuts will help fund increases in research and development and commercial support of new products, Rhyne said.
GSK employs about 15,000 people in the United States.
By Sathvik N
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.